Literature DB >> 11238210

Placental cellular immune response in women infected with human parvovirus B19 during pregnancy.

J A Jordan1, D Huff, J A DeLoia.   

Abstract

Human parvovirus B19 can cause congenital infection with variable morbidity and mortality in the fetus and neonate. Although much information exists on the B19-specific antibody response in pregnant women, little information is available describing the cell-mediated immune (CMI) response at the maternal-fetal interface. The focus of this study was to characterize the CMI response within placentas from women who seroconverted to B19 during their pregnancies and compare it to controls. Immunohistochemical techniques were used to identify the various immune cells and the inflammatory cytokine present within placental tissue sections. Group 1 consisted of placentas from 25 women whose pregnancies were complicated by B19 infection; 6 women with good outcome (near-term or term delivery), and 19 with poor outcome (spontaneous abortion, nonimmune hydrops fetalis, or fetal death). Group 2 consisted of placentas from 20 women whose pregnancies were complicated with nonimmune hydrops fetalis of known, noninfectious etiology. Group 3 consisted of placentas from eight women whose pregnancies ended in either term delivery or elective abortion. The results of the study revealed a statistically significant increase in the number of CD3-positive T cells present within placentas from group 1 compared to group 2 or 3 (13.3 versus 2 and 1, respectively) (P < 0.001). In addition, the inflammatory cytokine interleukin 2 was detected in every placenta within group 1 but was absent from all placentas evaluated from groups 2 and 3. Together, these findings demonstrate evidence for an inflammation-mediated cellular immune response within placentas from women whose pregnancies are complicated with B19 infection.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11238210      PMCID: PMC96051          DOI: 10.1128/CDLI.8.2.288-292.2001

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  37 in total

1.  Comparison of a baculovirus-based VP2 enzyme immunoassay (EIA) to an Escherichia coli-based VP1 EIA for detection of human parvovirus B19 immunoglobulin M and immunoglobulin G in sera of pregnant women.

Authors:  J A Jordan
Journal:  J Clin Microbiol       Date:  2000-04       Impact factor: 5.948

2.  Pathogenetic implication of interleukin-2 expressed in preeclamptic decidual tissues: a possible mechanism of deranged vasculature of the placenta associated with preeclampsia.

Authors:  Y Hamai; T Fujii; T Yamashita; S Kozuma; T Okai; Y Taketani
Journal:  Am J Reprod Immunol       Date:  1997-08       Impact factor: 3.886

3.  An epidemic of parvovirus B19 in a population of 3,596 pregnant women: a study of sociodemographic and medical risk factors.

Authors:  I P Jensen; P Thorsen; B Jeune; B R Møller; B F Vestergaard
Journal:  BJOG       Date:  2000-05       Impact factor: 6.531

Review 4.  Parvovirus B19 infection and its significance in pregnancy.

Authors:  G L Gilbert
Journal:  Commun Dis Intell       Date:  2000-03

5.  Immediate and long term outcome of human parvovirus B19 infection in pregnancy.

Authors:  E Miller; C K Fairley; B J Cohen; C Seng
Journal:  Br J Obstet Gynaecol       Date:  1998-02

6.  Correlation between cytokine levels of amniotic fluid and histological chorioamnionitis in preterm delivery.

Authors:  H Negishi; H Yamada; M Mikuni; T Kishida; K Okuyama; T Sagawa; S Makinoda; S Fujimoto
Journal:  J Perinat Med       Date:  1996       Impact factor: 1.901

7.  Cytokine production and cytokine receptor expression by cells of the human first trimester placental-uterine interface.

Authors:  P P Jokhi; A King; Y W Loke
Journal:  Cytokine       Date:  1997-02       Impact factor: 3.861

8.  Screening for cytokine mRNA in human villous and extravillous trophoblasts using the reverse-transcriptase polymerase chain reaction (RT-PCR).

Authors:  A King; P P Jokhi; S K Smith; A M Sharkey; Y W Loke
Journal:  Cytokine       Date:  1995-05       Impact factor: 3.861

9.  A human parvovirus-like virus inhibits haematopoietic colony formation in vitro.

Authors:  P P Mortimer; R K Humphries; J G Moore; R H Purcell; N S Young
Journal:  Nature       Date:  1983 Mar 31-Apr 6       Impact factor: 49.962

10.  Lymphoproliferative responses after infection with human parvovirus B19.

Authors:  A von Poblotzki; C Gerdes; U Reischl; H Wolf; S Modrow
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

View more
  6 in total

Review 1.  Parvovirus B19 infection in human pregnancy.

Authors:  R F Lamont; J D Sobel; E Vaisbuch; J P Kusanovic; S Mazaki-Tovi; S K Kim; N Uldbjerg; R Romero
Journal:  BJOG       Date:  2010-10-13       Impact factor: 6.531

2.  Enhanced Th17 phenotype in uninfected neonates born from viremic HIV-1-infected pregnant women.

Authors:  Joana Hygino; Morgana M Vieira; Landi V Guillermo; Renato G Silva-Filho; Carmen Saramago; Agostinho A Lima-Silva; Regis M Andrade; Arnaldao F B Andrade; Rodrigo M Brindeiro; Amilcar Tanuri; Vander Guimarães; Cleonice Alves de Melo Bento
Journal:  J Clin Immunol       Date:  2010-12-07       Impact factor: 8.317

3.  Long term follow up of serostatus after maternofetal parvovirus B19 infection.

Authors:  J Dembinski; A M Eis-Hübinger; J Maar; R Schild; P Bartmann
Journal:  Arch Dis Child       Date:  2003-03       Impact factor: 3.791

4.  Large scale aggregate microarray analysis reveals three distinct molecular subclasses of human preeclampsia.

Authors:  Katherine Leavey; Shannon A Bainbridge; Brian J Cox
Journal:  PLoS One       Date:  2015-02-13       Impact factor: 3.240

Review 5.  Is the ZIKV Congenital Syndrome and Microcephaly Due to Syndemism with Latent Virus Coinfection?

Authors:  Solène Grayo
Journal:  Viruses       Date:  2021-04-13       Impact factor: 5.048

Review 6.  Cytokines in parvovirus B19 infection as an aid to understanding chronic fatigue syndrome.

Authors:  Jonathan R Kerr; David A J Tyrrell
Journal:  Curr Pain Headache Rep       Date:  2003-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.